Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Lack of Commercial Oral Drug Formulations for Children in Two Hospital Group Purchasing Agreements in France and Canada

Author(s):  Prot-Labarthe Sonia, Bussieres Jean-Francois, Barett Pierre, Bourdon Olivier, Brion Francoise

Issue:  Jul/Aug 2008 - Hormone Replacement Therapy
View All Articles in Issue

Page(s):  365-367

Lack of Commercial Oral Drug Formulations for Children in Two Hospital Group Purchasing Agreements in France and Canada Page 1
Lack of Commercial Oral Drug Formulations for Children in Two Hospital Group Purchasing Agreements in France and Canada Page 2
Lack of Commercial Oral Drug Formulations for Children in Two Hospital Group Purchasing Agreements in France and Canada Page 3

Download in electronic PDF format for $75

Abstract:  There are a limited number of commercial oral pediatric drug formulations on the market. The incidence of available commercial oral formulations for children has not been studied to date. This study compared the number and the characteristics of oral pediatric drug formulations listed on two hospital group purchasing agreements for the two large urban areas (e.g., Paris and Montreal), valid on April 1, 2006. Variables collected were the brand and the generic name product, the anatomical therapeutic chemical classification, the drug formulation, and the dispensing tool. Throughout this study, we identified that there was a total of 191 and 151 commercial oral pediatric drug formulations corresponding to 127 and 94 generic name products, respectively in Paris and Montreal. The three main anatomical therapeutic chemical classification classes are alimentary tract and metabolism drugs, systemic anti-infectives, and drugs acting on nervous system. There are only 47 generic names common to both group purchasing agr

Related Keywords: Sonia Prof-LaBarthe, DPharm, PhD, Jean-Francois Bussieres, BPharm, MSc, MBA, CSHP, Pierre Barret, Olivier Bourdon, DPharm, PhD, MBA, Francoise Brion, DPharm, PhD, children, hospital pharmacy, oral formulations, Canada, France, dosage forms

Related Categories: LEGAL, PEDIATRICS, PEER-REVIEWED, DOSAGE FORMS/DRUG CARRIERS

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Lack of Commercial Oral Drug Formulations for Children in Two Hospital Group Purchasing Agreements in France and Canada
Prot-Labarthe Sonia
, Bussieres Jean-Francois, Barett Pierre, Bourdon Olivier, Brion Francoise
Jul/Aug 2008
Pg. 365-367

The Value of Near Infrared Spectroscopy in a Small Hospital Compounding Unit to Control the Risks Associated with Raw Materials
Storme-Paris Isabelle
, Storme Thomas, Thauvin Maxime, Brion Francoise, Chaminade Pierre, Rieutord Andre
Jan/Feb 2009
Pg. 81-86

Chemical Stability of Extemporaneously Compounded Omeprazole Formulations: A Comparison of Two Methods of Compounding
Garg Sanjay
, Svirskis Darren, Al-Kabban Majid, Farhan Samer, Komeshi Mohammed, Lee Jacky, Liu Quincy, Naidoo Sacha, Kairuz Therese
May/Jun 2009
Pg. 250-253

The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions
Svirskis Darren
, Lin Shao-Wei, Brown Helen, Sangaroomthong Annie, Shin Daniel, Wang Ziqi, Xu Hongtao, Dean Rebecca, Vareed Preetika, Jensen Maree, Wu Zimei
Mar/Apr 2018
Pg. 164-171

Determining the Availability of a Commercial Drug
Jan/Feb 2003
Pg. 44-45

Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh
Allen Loyd V Jr
Nov/Dec 2003
Pg. 449-450

Standard Operating Procedure: Determining and Documenting the Commercial Unavailability of a Manufactured Drug Product
Allen Loyd V Jr
Jul/Aug 2004
Pg. 292-293

Need for Appropriate Formulations for Children: The National Institute of Child Health and Human Development--Pediatric Formulations Initiative, Part 2
Giacoia George P
, Taylor-Zapata Perdita, Mattison Donald
May/Jun 2007
Pg. 220-225

Hospital Compounding in Nigeria: A Review of Needs, Practice, and Suggestions for Pharmaceutical Dispensing Ciurriculum Development
Orubu Ebiowei Samuel F
, Patani Bernard Opatimidi, Arhewoh Matthew Ikhuoria
Nov/Dec 2021
Pg. 475-481

Pediatric Compounding: Coloring Outside the Lines
Preckshot John
Jan/Feb 2001
Pg. 6-8

Room Temperature Stability of Injectable Succinylcholine Dichloride
Roy Julie J
, Boismenu Daniel, Mamer Orval A, Nguyen Bao T, Forest Jean-Marc, Hildgen Patrice
Jan/Feb 2008
Pg. 83-85

Purchasing Chemicals for Pharmaceutical Compounding
Allen Loyd V Jr
Jan/Feb 2001
Pg. 67-68

Zinc Content of Commercial Diluents Widely Use in Drug Admixtures Prepared for Intravenous Infusion
Desai Narendra R
, Shah Syed M, Koczone Julianna, Vencl-Joncic Maja, Sisto Christopher, Ludwig Stephen A
Sep/Oct 2007
Pg. 426-432

Oral Rehydration Salts (World Health Organization/United Nations Children's Fund)
Allen Loyd V Jr
Sep/Oct 2006
Pg. 390

Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs
Dillon L R
Jan/Feb 2020
Pg. 30-36

Roboticized Compounding of Oncology Drugs in a Hospital Pharmacy
Palma Elisabetta
, Bufarini Celestino
Sep/Oct 2014
Pg. 358-364

Microwave Freeze-thaw Technique for Injectable Drugs: A Review Updated from 1980 to 2021
Hecq Jean-Daniel
, Soumoy Laura, Closset Mélanie, Colsoul Marie-Lise, Jamart Jacques, Galanti Laurence
Nov/Dec 2021
Pg. 446-462

In Vitro Permeability, Irritability, and Release Evaluation of Commonly Used Topical Diclofenac Gel Preparations (1%, 5%, and 10%)
Kohan Hamed Gilzad
, Baker David M, Sani Shabnam, Bielecki-Wilken Kathleen A, Ramirez Alfonso
Mar/Apr 2021
Pg. 146-155

Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients
Allen Loyd V Jr
Nov/Dec 2023
Pg. 474-481

Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children
Nahata Milap C
May/Jun 2016
Pg. 247-249

Return to Top